Nycomed News RSS feedhttp://www.nycomed.com/News.aspxNewsenhttp://www.nycomed.com/~/media/Countries/www_nycomed_com/Settings/img_logo.ashx?20100422T1216486111Nycomed News RSS feedhttp://www.nycomed.com/News.aspxWed, 01 Sep 2010 08:47:49 GMTWed, 01 Sep 2010 08:47:49 GMTFrom Oranienburg to the rest of the world: global market launch of Daxas® (Roflumilast) kicks off in Germanyhttp://www.nycomed.com/News/News-Releases/2010/from-oranienburg-to-the-rest-of-the-world---global-market-launch-of-daxas.aspxWed, 01 Sep 2010 08:47:49 GMThttp://www.nycomed.com/News/News-Releases/2010/from-oranienburg-to-the-rest-of-the-world---global-market-launch-of-daxas.aspxNycomed achieved significant milestone in second quarter 2010http://www.nycomed.com/News/News-Releases/2010/nycomed-achieved-significant-milestone-in-second-quarter-2010.aspxTue, 17 Aug 2010 07:42:48 GMThttp://www.nycomed.com/News/News-Releases/2010/nycomed-achieved-significant-milestone-in-second-quarter-2010.aspxNycomed’s U.S. patent for Protonix® (pantoprazole) validhttp://www.nycomed.com/News/News-Releases/2010/Nycomeds%20US%20patent%20for%20Protonix%20pantoprazole%20valid.aspxMon, 19 Jul 2010 07:31:07 GMThttp://www.nycomed.com/News/News-Releases/2010/Nycomeds%20US%20patent%20for%20Protonix%20pantoprazole%20valid.aspxNycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) receives marketing authorisation in the European Union for patients with COPDhttp://www.nycomed.com/News/News-Releases/2010/Nycomeds%20novel%20anti-inflammatory%20therapy%20Daxas%20receives%20marketing%20authorisation%20in%20EU.aspxTue, 06 Jul 2010 11:46:21 GMThttp://www.nycomed.com/News/News-Releases/2010/Nycomeds%20novel%20anti-inflammatory%20therapy%20Daxas%20receives%20marketing%20authorisation%20in%20EU.aspxNycomed and Forest Laboratories receive complete FDA response letter for Roflumilast – no additional patient trials were requestedhttp://www.nycomed.com/News/News-Releases/2010/Nycomed%20and%20Forest%20Laboratories%20receive%20complete%20FDA%20response%20letter%20for%20Roflumilast.aspxSun, 16 May 2010 22:00:00 GMThttp://www.nycomed.com/News/News-Releases/2010/Nycomed%20and%20Forest%20Laboratories%20receive%20complete%20FDA%20response%20letter%20for%20Roflumilast.aspxNycomed’s first quarter 2010 results confirm the directionhttp://www.nycomed.com/News/News-Releases/2010/Nycomeds%20first%20quarter%202010%20results%20confirm%20the%20direction.aspxTue, 11 May 2010 15:33:00 GMThttp://www.nycomed.com/News/News-Releases/2010/Nycomeds%20first%20quarter%202010%20results%20confirm%20the%20direction.aspxGE Healthcare and Nycomed to form joint venture to sell, market and distribute medical diagnostic contrast agents in Russia and CIShttp://www.nycomed.com/News/News-Releases/2010/GE%20Healthcare%20and%20Nycomed%20to%20form%20joint%20venture.aspxMon, 26 Apr 2010 22:00:00 GMThttp://www.nycomed.com/News/News-Releases/2010/GE%20Healthcare%20and%20Nycomed%20to%20form%20joint%20venture.aspxNycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® in Europe and Canadahttp://www.nycomed.com/News/News-Releases/2010/Nycomed%20and%20Merck%20Co%20Inc%20announce%20commercialization%20agreements%20for%20Daxas%20in%20Europe%20and%20Canada.aspxSun, 25 Apr 2010 22:00:00 GMThttp://www.nycomed.com/News/News-Releases/2010/Nycomed%20and%20Merck%20Co%20Inc%20announce%20commercialization%20agreements%20for%20Daxas%20in%20Europe%20and%20Canada.aspxJury renders positive findings on US pantoprazole (Protonix®) patenthttp://www.nycomed.com/News/News-Releases/2010/Jury%20renders%20positive%20findings%20on%20US%20pantoprazole%20Protonix%20patent.aspxThu, 22 Apr 2010 22:00:00 GMThttp://www.nycomed.com/News/News-Releases/2010/Jury%20renders%20positive%20findings%20on%20US%20pantoprazole%20Protonix%20patent.aspxNycomed’s novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union for patients with COPD http://www.nycomed.com/News/News-Releases/2010/Nycomed%20novel%20anti-inflammatory%20therapy.aspxThu, 22 Apr 2010 22:00:00 GMThttp://www.nycomed.com/News/News-Releases/2010/Nycomed%20novel%20anti-inflammatory%20therapy.aspx